Novapep is an early stage biotech company which has secured the exclusive world-wide license for the novel patented peptide TR47 from the Scripps Research Institute.
Novapep is researching the potential of TR47 in vasculitis, nephritis, atopic dermatitis and autoimmune diseases, based on strong supporting scientific data.
Seed funding has been raised and the University of Sydney is an investor.
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.